iRadimed(US:IRMD)2025-11-03 13:30Financial Performance - The Company reported record revenue of $21.2 million for Q3 2025, a 16% increase year-over-year from $18.3 million in Q3 2024[3] - GAAP diluted earnings per share (EPS) for Q3 2025 were $0.43, an 8% increase compared to $0.40 in Q3 2024, while non-GAAP diluted EPS was $0.47, a 9% increase from $0.43[7] - Non-GAAP net income for Q3 2025 was $6.1 million, a 10% increase from $5.5 million in Q3 2024[9] - Net income for Q3 2025 reached $5,576,652, a 10.4% increase compared to $5,049,491 in Q3 2024[39] - Revenue for Q3 2025 was $21,202,064, representing a 15.5% increase from $18,325,959 in Q3 2024[39] - Gross profit for Q3 2025 was $16,494,308, up 16.2% from $14,191,706 in Q3 2024[39] - Free cash flow for Q3 2025 was $5,722,520, an increase from $5,104,230 in Q3 2024[43] Guidance and Expectations - The Company raised its full-year 2025 revenue guidance to $82.5 million to $83.5 million, up from the previous range of $80.0 million to $82.5 million[5] - For Q4 2025, the Company expects revenue between $21.4 million and $22.4 million, with GAAP diluted EPS guidance of $0.43 to $0.47[18] - The company expects to ramp up commercialization of its next-generation 3870 MRI-compatible IV infusion pump, with anticipated revenue growth[34] Operational Efficiency - The gross margin for Q3 2025 was 78%, compared to 77% in Q3 2024, indicating improved operational efficiency[14] - Operating expenses for Q3 2025 were $9,660,558, up from $8,402,586 in Q3 2024, representing a 14.9% increase[39] Cash Flow and Assets - Cash flow from operations for Q3 2025 was $7.0 million, a decrease of 23% from $9.1 million in Q3 2024[15] - Total current assets increased to $84,919,005 as of September 30, 2025, compared to $74,706,209 at the end of 2024, marking a 13.7% growth[37] - Total assets rose to $114,721,779 as of September 30, 2025, up from $98,325,775 at the end of 2024, indicating a 16.7% increase[37] - Total stockholders' equity increased to $98,351,971 as of September 30, 2025, compared to $86,818,756 at the end of 2024, reflecting a 13.4% growth[37] Sales and Market Presence - Domestic sales accounted for 85% of total revenue in Q3 2025, up from 83% in Q3 2024[14] - The total construction cost of the new facility in Orlando was approximately $13.3 million, completed in early July 2025[17] Product Development - The Company plans to begin limited commercial shipments of the next-generation 3870 MRI-compatible IV infusion pump in December 2025, with full U.S. commercialization expected in Q1 2026[4]